Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 3/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24596291 | 0.72 | ABL1 (0.49) | ALDH1A1ALPLS1PR4ABL1 | |
| SCHEMBL24986936 | 0.71 | KMO (0.49) | ALDH1A1KMOALPLS1PR4ABL1 | |
| SCHEMBL24596346 | 0.70 | NPSR1 (0.38) | ALDH1A1 | |
| SCHEMBL18004030 | 0.69 | KDM4E (0.42) | ALDH1A1KMOALPLS1PR4 | |
| SCHEMBL2464148 | 0.68 | ABL1 (0.42) | ALDH1A1KMOALPLS1PR4PDE4B | |
| SCHEMBL1477994 | 0.68 | ABL1 (0.42) | ALDH1A1KMOALPLS1PR4ABL1 | |
| SCHEMBL25227263 | 0.68 | GRM2 (0.41) | ALDH1A1KMOALPLS1PR4ABL1 | |
| SCHEMBL3329122 | 0.68 | ABL1 (0.45) | ALDH1A1KMOALPLS1PR4ABL1 | |
| SCHEMBL26115204 | 0.68 | EGFR (0.51) | ABL1PTGS1PTGS2CNR1 | |
| Hydrochloric Acid SCHEMBL581298 | 0.68 | KDM4C (0.55) | KMOALPLTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124454-A1 | TRICYCLIC COMPOUND AND USE THEREOF | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-116670144-A | Tricyclic compounds and uses thereof | 南京再明医药有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2022143864-A1 | TRICYCLIC COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022143864-A1 | TRICYCLIC COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124454-A1 | TRICYCLIC COMPOUND AND USE THEREOF | MAT2A, MNAT1, KAT2A | ALDH1A1 1518/4885KMO 3509/4885ALPL 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.